Successful treatment of systemic AL amyloidosis with autologous hematopoietic stem cell transplantation combined with cell‐free and concentrated ascites reinfusion therapy

Abstract

Key Clinical Message AL patients develop the unique toxicities of fluid retention and non‐cardiogenic pulmonary edema during the course of stem cell mobilization. We propose mobilization with CART as effective and safe treatment for AL patients with refractory anasarca. Abstract We describe a 63‐year‐old male with systemic immunoglobulin light chain (AL) amyloidosis with cardiac, renal, and liver involvement. After four courses of CyBorD, mobilization with G‐CSF at 10 μg/kg was initiated and CART was simultaneously performed for fluid retention. No adverse events were observed during collection or reinfusion. Anasarca gradually disappeared and he underwent autologous hematopoietic stem cell transplantation. The complete remission of AL amyloidosis has been maintained, and the condition of the patient has remained stable for 7 years. We propose mobilization with CART as an effective and safe treatment option for AL patients with refractory anasarca.

Keywords

• cardiac involvement
• cell‐free and concentrated ascites reinfusion therapy (CART)
• hematopoietic stem cell transplantation (HSCT)
• immunoglobulin light chain (AL) amyloidosis